Degludec Review Could Lead To New CV Safety Requirements For Insulins
Executive Summary
During an advisory committee review of Novo Nordisk’s long-acting basal insulin, FDA raises concerns about a cardiovascular risk signal seen across a meta-analysis of clinical trials, although insulins have been excluded from CV safety requirements for type 2 diabetes drugs.